StockpollyBeta
Get App
Popularity #2,160
CRVS · NASDAQ · Biotechnology

Corvus Pharmaceuticals (CRVS)

Develops immune-disease and cancer therapies centered on soquelitinib.

$12.26
vs last close−1.18 (−8.78%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Cost of revenue000000000000
Gross profit000000000000
666678101011121519
Research & development444456788101116
222222222243
General & administrative222222222243
Operating income−6−6−6−6−7−8−10−10−11−12−15−19
0−112−33−42520012
Interest income000011111−200
Interest expense000000000020
Other non-operating income01−1−2334−25−200−3−2
Income before tax−6−7−6−4−40−1215−8−10−12−14−17
Income tax expense000000000001
Net income from continuing operations−6−7−6−4−40−1215−8−10−12−14−18
Net income−6−7−6−4−40−1215−8−10−12−14−18
EPS, basic−$0.12−$0.14−$0.12−$0.07−$0.60−$0.18$0.21−$0.10−$0.12−$0.18−$0.15−$0.19
EPS, diluted−$0.12−$0.14−$0.12−$0.07−$0.60−$0.18−$0.13−$0.10−$0.12−$0.18−$0.15−$0.19
Weighted average shares, basic494949606768727883799092
Weighted average shares, diluted494949606768757883809092
EBITDA−6−7−6−4−40−1215−8−10−12−12−17
Depreciation & amortization000000000000
EBIT−6−7−6−4−40−1215−8−10−12−12−17